Stock · EW · Healthcare
United States · Large Cap · listed since 2000 · Revenue 12 mo. $6.5B
Price as of 11/06/2026
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Original text from the data provider
Summary
55.3 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €1.2B (2025), it supports €13.3B. The remaining €38.8B of the market value assume it grows 19.0% a year for 10 years and not at all afterwards.
Required FCF growth per year
19.0%
no growth afterwards
Price to operating cash flow 34.3×, below its usual range.
Middle half of 13 quarters: 37.7× to 43.0×, median 40.5×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
5 more unchanged: Revenue, 12 mo., Gross margin, EBIT margin, Shares outstanding, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 10.38% | 11.52% | Rank 44 |
| Return on capital (Greenblatt) | 23.92% | 32.55% | Rank 32 |
| EBIT margin | 26.97% | 18.31% | Rank 75 |
| FCF margin | 22.00% | 14.12% | Rank 77 |
| Gross margin | 78.13% | 60.99% | Rank 82 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 11.55% | 8.04% | Rank 69 |
| Earnings growth, 3 years per year | −9.08% | 5.44% | Rank 20 |
| Earnings growth, 5 years per year | 7.06% | 7.00% | Rank 50 |
| Sustainable growth (ROE × retained earnings) | 4.29% | 3.66% | Rank 56 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 1.79% | 2.90% | Rank 25 |
| FCF yield | 2.30% | 3.63% | Rank 26 |
| EV/saleslower is better | 8.99 | 4.03 | Rank 19 |
| EV/EBITlower is better | 33.35 | 21.73 | Rank 23 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 14.29% | 8.66% | Rank 59 |
| Share price, 6 months | 28.22% | 24.27% | Rank 60 |
| Share price, 3 months | 18.97% | 15.42% | Rank 62 |
| Distance from 52-week high | 0.00% | −7.35% | Rank 96 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 1.43% | 0.30% | Rank 41 |
| Change in share countlower is better | −2.25% | 0.00% | Rank 82 |
| Dividend streak in years | – | 10 | Rank 13 |
| Price reaction to results, market-adjusted | −1.55% | 0.05% | Rank 30 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 75.47% | 48.40% | Rank 86 |
| Net debt/EBITDAlower is better | −2.46 | 1.11 | Rank 92 |
| Debt to equitylower is better | 0.07 | 0.48 | Rank 85 |
| Volatility, 1 yearlower is better | 25.04% | 31.42% | Rank 87 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF | Shares | Net debt |
|---|---|---|---|---|---|
| 2016 | 3.0 | 27.5% | $487.0M | 653M | −$107.8M |
| 2017 | 3.4 | 29.4% | $825.2M | 648M | $218.1M |
| 2018 | 3.7 | 29.3% | $685.1M | 641M | −$120.3M |
| 2019 | 4.3 | 27.6% | $901.0M | 637M | −$500.3M |
| 2020 | 4.4 | 29.6% | $647.0M | 632M | −$488.3M |
| 2021 | 5.2 | 30.8% | $1.4B | 631M | −$172.5M |
| 2022 | 5.4 | 31.6% | $953.4M | 624M | −$77.7M |
| 2023 | 6.0 | 25.6% | $629.5M | 609M | −$447.2M |
| 2024 | 5.4 | 25.4% | $289.9M | 599M | −$2.3B |
| 2025 | 6.1 | 27.0% | $1.3B | 586M | −$2.2B |
1 of 7 StockScorer Score rules met · How the score is built
Edwards Lifesciences Corp mainly meets criteria in the Profitability category. Result from 18 strategies checked.
Edwards Lifesciences Corp is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
1 of 7 rules met
2 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Edwards Lifesciences Corp.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 55.7 | 30.0 |
| P/B ratio | 5.8 | 4.8 |
| Return on equity (ROE) | 10.4% | 11.5% |
| Equity ratio | 75.5% | 48.4% |
| Debt-to-equity (D/E) | 0.07 | 0.48 |
| Dividend yield | 0.0% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| EW | Edwards Lifesciences Corpthis page | |
| BSX | Boston Scientific Corp | High9.1 |
| GEHC | GE HealthCare Technologies Inc. | Low4.5 |
| DXCM | DexCom Inc | High8.2 |
| STE | STERIS plc | locked |
| ZBH | Zimmer Biomet Holdings Inc | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.